## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

A	plica	nt(s):	Jacob Waugh et al.			
Se	rial N	o.:	10/591,485	Group Art Unit:	1656	
Fi	led:		November 7, 2007	Examiner: Confirmation No:	Samuel W. Liu	
For:			Confirmation No: 1919 Multi-Component Biological Transport Systems			
P.0	Э. Вох	x 1450 ria, V <i>A</i>	A 22313-1450			
α.		<u>SU</u>	PPLEMENTAL INFORMATIO	<u>N DISCLOSURE S</u>	<u>TATEMENT</u>	
Siı	•					
		,	This Information Disclosure Statem	ent is filed in accord	ance with 37 C.F.R.	
§§	1.56, 1	1.97 an	d 1.98. The items listed on Form P	TO-SB08, a copy of	which is enclosed, are	
ma	de of	record	to assist the Patent and Trademark	Office in its examina	ation of this application.	
Th	e Exar	miner i	s respectfully requested to fully cor	sider the items and t	o independently ascertain	
the	ir teac	hing.				
1.		not ii	ach of the following items listed on the English language, an English l of or a concise explanation of the re	anguage translation	of that item or a portion	
2.		not ir	ach of the following items listed on the English language, a concise ex porated in the specification of the a	planation of the rele	vance of that item is	
3.		enclo	copy of the items listed on the enclosed with this Information Disclosur itted to the Patent and Trademark C	e Statement was pre-	viously cited by or	
			_•			
4.	$\boxtimes$		e is due under 37 C.F.R. §1.17(p) for it is being filed in compliance with		pisclosure Statement	
			37 C.F.R. §1.97(b)(1), within three application other than a CPA; or	ee months of the filin	g date of a national	
			37 C.F.R. §1.97(b)(2), within three national stage as set forth in §1.49		•	

	$\boxtimes$	37 C.F.R. §1.97(b)(3), before the mailing date of a first Office action on the merits; or	
		37 C.F.R. §1.97(b)(4) before the mailing date of a first office action after the filing of an RCE under §1.114.	
5.	No fee is due under 37 C.F.R. §1.17(p) for this Information Disclosure Statement since it is being filed in compliance with 37 C.F.R. §1.97(c), after the period specin paragraph 4 above but before the mailing date of a final action or a Notice of Allowance (where there has been no prior final action), and is accompanied by or the certifications pursuant to 37 C.F.R. §1.97(e) set forth in paragraph 9 below.		
6.	it is be	is due under 37 C.F.R. §1.17(p) for this Information Disclosure Statement since eing filed in compliance with 37 C.F.R. §1.97(c), after the period specified in raph 4 above but before the mailing date of a final action or a notice of ance (where there has been no prior final action):	
		A check in the amount of \$180.00 is enclosed in payment of the fee.	
		Charge the fee to Deposit Account No. <u>50-3732</u> , Order No	
7.	A fee is due under 37 C.F.R. §1.17(p) for this Information Disclosure Statement since it is being filed in compliance with 37 C.F.R. §1.97(d), after the mailing date of a final action or a notice of allowance, whichever comes first, but before payment of the issue fee, and is accompanied by:		
		ne of the certifications pursuant to 37 C.F.R. §1.97(e) set forth in paragraph 9 elow; and	
		e fee due under 37 C.F.R. §1.17(p) which is paid as set forth in paragraph 11 elow.	
8.	This I	nformation Disclosure Statement is being filed in compliance with:	
	a. 🗌	37 C.F.R. §1.313(b)(3) or §1.313(c)(1), after the issue fee has been paid and information cited in this Information Disclosure Statement may render at least one claim unpatentable and is accompanied by the attached Petition To Withdraw Application From Issue and fee pursuant to 37 C.F.R. §1.17(h);	
	b. 🗌	37 C.F.R. §1.313(c)(2) or §1.313(c)(3), after the issue fee has been paid and information cited in this Information Disclosure Statement is to be considered in a Request for Continued Examination (RCE) or a Continuation application upon abandonment of the instant application and is accompanied by the attached Petition To Withdraw Application From Issue and fee pursuant to 37 C.F.R. §1.17(h).	
	c	The fee due under 37 C.F.R. §§1.17(h) is paid as set forth in paragraph 11 below.	
9.		by certify that each item of information contained in this Information Disclosure ent was first cited in a communication from a foreign patent office in a	

	counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement.
	I hereby certify that no item of information in the Information Disclosure Statement filed herewith was cited in a communication from a foreign patent office in a counterpart foreign application or, to my knowledge after making reasonable inquiry, was known to any individual designated in §1.56(c) more than three months prior to the filing of this Information Disclosure Statement.
10.	This document is accompanied by a Search Report Communication which was cited in a corresponding PCT or Foreign counterpart application.
11.	A check in the amount of \$ is enclosed in payment of the fees due under 37 C.F.R. §§1.17(h) and 1.17(p).
	Charge any fees due under 37 C.F.R. §§1.17(h) and 1.17(p) to Deposit Account No. 50-3732, Order No
	The Commissioner is hereby authorized to charge any additional fees which may be required for this Information Disclosure Statement, or credit any overpayment to Deposit Account No. 50-3732, Order No. 13720-105074.
Dated: Ju	Respectfully submitted, KING & SPALDING LLP  By:  Jøseph D, Eng, Jr.
Correspor	Regl. No. 54,084 O O ndence Address:
TZ' 0 0	11: 11.0

King & Spalding LLP 1185 Avenue of the Americas New York, NY 10036 212-556-2100 Telephone 212-556-2222 Facsimile

1068274 vI -3-